HUMAN+ is established to make the development of new pharmaceutical products and diagnostics more effective and to accelerate the development process. HUMAN+ organises structural availability of international experts and collaboration among public- and private funders to foster effective project selection and product development.
Development of new pharmaceutical products is stagnating. Though new discoveries arise at an ever-increasing pace, translation of biomedical research outcomes into new products for patients does not match this pace.
HUMAN+ is established by Privium Fund Management, initiator of innovative investment funds, in collaboration with the Netherlands Organization for Health Research (ZonMw), Reumafonds, the Cooperation of NL Health Charities (SGF), INKEF Capital and two family offices. These ‘Founding Members’ contributed to the establishment of HUMAN+ and offer their expertise.